404 related articles for article (PubMed ID: 32294917)
1. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
2. Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis.
Zhou J; Guo D; Zhang Y; Wu W; Ran H; Wang Z
ACS Appl Mater Interfaces; 2014 Apr; 6(8):5566-76. PubMed ID: 24693875
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
[TBL] [Abstract][Full Text] [Related]
4. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis.
Yang HW; Hua MY; Lin KJ; Wey SP; Tsai RY; Wu SY; Lu YC; Liu HL; Wu T; Ma YH
Int J Nanomedicine; 2012; 7():5159-73. PubMed ID: 23055728
[TBL] [Abstract][Full Text] [Related]
5. Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
Huang L; Wang J; Huang S; Siaw-Debrah F; Nyanzu M; Zhuge Q
Biochem Biophys Res Commun; 2019 Aug; 516(2):565-570. PubMed ID: 31235258
[TBL] [Abstract][Full Text] [Related]
6. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
7. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis induced by intravenous administration of plasminogen activator in magnetoliposomes: dual targeting by magnetic and thermal manipulation.
Liu CH; Hsu HL; Chen JP; Wu T; Ma YH
Nanomedicine; 2019 Aug; 20():101992. PubMed ID: 30981818
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion.
Zhang H; Han S; Zhang L; Guo Y; Li Y
Cell Mol Biol (Noisy-le-grand); 2022 Mar; 68(3):201-212. PubMed ID: 35988180
[TBL] [Abstract][Full Text] [Related]
10. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles.
Ma YH; Wu SY; Wu T; Chang YJ; Hua MY; Chen JP
Biomaterials; 2009 Jul; 30(19):3343-51. PubMed ID: 19299010
[TBL] [Abstract][Full Text] [Related]
11. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B
Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Catheter Based rtPA Thrombolysis in a Novel In Vitro Clot Model for Intracerebral Hemorrhage.
Keric N; Masomi-Bornwasser J; Müller-Werkmeister H; Kantelhardt SR; König J; Kempski O; Giese A
Biomed Res Int; 2017; 2017():5472936. PubMed ID: 28459065
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.
Keric N; Döbel M; Krenzlin H; Kurz E; Tanyildizi Y; Heimann A; König J; Kempski O; Ringel F; Masomi-Bornwasser J
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105073. PubMed ID: 32807475
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
Sivaraman B; Sylvester A; Ramamurthi A
Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():145-156. PubMed ID: 26652359
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
[TBL] [Abstract][Full Text] [Related]
16. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
Tadayon A; Jamshidi R; Esmaeili A
Int J Pharm; 2015 Nov; 495(1):428-438. PubMed ID: 26363110
[TBL] [Abstract][Full Text] [Related]
17. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke.
Peng T; Booher K; Moody MR; Yin X; Aronowski J; McPherson DD; Savitz SI; Kim H; Huang SL
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627321
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots.
Vankayala R; Corber SR; Mac JT; Rao MP; Shafie M; Anvari B
Macromol Biosci; 2018 Apr; 18(4):e1700379. PubMed ID: 29479820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
